Compare PRGO & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRGO | VCEL |
|---|---|---|
| Founded | 1887 | 1989 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 1991 | 1997 |
| Metric | PRGO | VCEL |
|---|---|---|
| Price | $13.25 | $37.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $22.50 | ★ $60.40 |
| AVG Volume (30 Days) | ★ 4.1M | 573.8K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 8.63% | N/A |
| EPS Growth | N/A | ★ 236.54 |
| EPS | N/A | ★ 0.25 |
| Revenue | ★ $4,281,800,000.00 | $258,716,999.00 |
| Revenue This Year | N/A | $17.86 |
| Revenue Next Year | N/A | $18.55 |
| P/E Ratio | ★ N/A | $146.91 |
| Revenue Growth | N/A | ★ 14.05 |
| 52 Week Low | $12.17 | $29.24 |
| 52 Week High | $30.93 | $63.00 |
| Indicator | PRGO | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 31.07 | 46.91 |
| Support Level | $13.34 | $35.85 |
| Resistance Level | $14.12 | $42.68 |
| Average True Range (ATR) | 0.47 | 1.77 |
| MACD | 0.32 | -0.52 |
| Stochastic Oscillator | 55.64 | 18.39 |
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.